{"id":35735,"date":"2026-03-20T13:26:09","date_gmt":"2026-03-20T13:26:09","guid":{"rendered":"https:\/\/www.europesays.com\/ch\/35735\/"},"modified":"2026-03-20T13:26:09","modified_gmt":"2026-03-20T13:26:09","slug":"novartis-acquires-synnovations-breast-cancer-drug-for-up-to-3-billion","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/ch\/35735\/","title":{"rendered":"Novartis acquires Synnovation’s breast cancer drug for up to $3 billion"},"content":{"rendered":"

\"Novartis<\/a>Novartis today announced that it has entered into an agreement with Synnovation Therapeutics, LLC to acquire SNV4818, a pan-mutant\u2011selective PI3K\u03b1 inhibitor, exploring a next-generation approach for the treatment of patients with HR+\/HER2- breast cancer and potentially other solid tumor indications.<\/p>\n

SNV4818 is an oral drug currently being evaluated in a Phase 1\/2 study for breast cancer and other advanced solid tumors. The biology of mutated PI3K\u03b1 in HR+\/HER2- breast cancer is well-understood, with approximately 40% of HR+\/HER2- breast cancer patients potentially facing worse disease prognosis due to the presence of PIK3CA mutations in their tumors. The program is aligned with the Novartis commitment to developing treatments that improve the lives of patients with breast cancer. It fits naturally alongside CDK inhibitors as well as endocrine (hormonal) therapies as part of a potential combination regimen.\u00a0<\/p>\n

\u201cWhile mutated PI3K\u03b1 is a well\u2011established driver in HR+\/HER2\u2011 breast cancer, there remains a challenge in achieving effective pathway inhibition with a tolerable therapeutic profile,\u201d said Shreeram Aradhye, M.D., president of development at Novartis. \u201cSNV4818 applies new mutant\u2011selective chemistry to more precisely target tumor biology while sparing normal cells. This approach has the potential to translate proven biology into improved tolerability and more durable benefit for patients through precision medicine.\u201d<\/p>\n

SNV4818 is designed to target the mutated PI3K\u03b1 enzyme found in cancer cells while sparing the wild-type (normal) PI3K\u03b1 in healthy cells. Available PI3K\u03b1 inhibitors block both mutant and wild-type PI3K\u03b1, leading to tolerability challenges that make it difficult to keep patients on treatment. By focusing on the mutated form in tumors, SNV4818 aims to reduce unwanted side effects, support more consistent dosing, and make it easier to combine with hormonal therapy and other treatments earlier in care. Preclinical studies show strong activity against common PIK3CA mutations and clear selectivity over the normal enzyme, with clinical evaluation ongoing.\u00a0<\/p>\n

Under the terms of the agreement, Novartis will pay $2 billion upfront and up to $1 billion in milestone payments to Synnovation Therapeutics, LLC to acquire Pikavation Therapeutics, Inc., a wholly- owned subsidiary of Synnovation that holds a portfolio of pan-mutant selective PI3K\u03b1 inhibitor programs, including SNV4818. The transaction is expected to close in H1 2026, subject to the satisfaction or waiver of customary closing conditions, including regulatory approvals.\u00a0<\/p>\n","protected":false},"excerpt":{"rendered":"Novartis today announced that it has entered into an agreement with Synnovation Therapeutics, LLC to acquire SNV4818, a…\n","protected":false},"author":2,"featured_media":18396,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[127],"tags":[3264,207,2112,206,265,21187,6304,21016,13414],"class_list":{"0":"post-35735","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-novartis","8":"tag-acquisition","9":"tag-breast-cancer","10":"tag-cancer","11":"tag-novartis","12":"tag-oncology","13":"tag-oral-drug","14":"tag-precision-medicine","15":"tag-synnovation-therapeutics","16":"tag-tumors"},"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@ch\/116261734610425512","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/35735","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/comments?post=35735"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/35735\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media\/18396"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media?parent=35735"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/categories?post=35735"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/tags?post=35735"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}